AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35320960 — intervention group
Group type: COMPARATOR
Intervention: Both approaches (Median and Paramedian)
Number of subjects: 100
Study 32677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR)
Number of subjects: 92
Study 32677982 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 92
Study 34197173 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad belief induction task
Number of subjects: 0
Study 34197173 — intervention group
Group type: COMPARATOR
Intervention: Narrow belief induction task
Number of subjects: 0
Study 34197173 — intervention group
Group type: EXPERIMENTAL
Intervention: Film clip viewing
Number of subjects: 0
Study 34131075 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Facebook users
Number of subjects: 0
Study 34131075 — intervention group
Group type: COMPARATOR
Intervention: Deactivated Facebook profiles
Number of subjects: 0
Study 32197408 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet (HD)
Number of subjects: 125
Study 32197408 — intervention group
Group type: EXPERIMENTAL
Intervention: HD plus De Simone Formulation probiotic blend
Number of subjects: 125
Study 32197408 — intervention group
Group type: EXPERIMENTAL
Intervention: HD plus AISA d-Limonene
Number of subjects: 125
Study 32197408 — intervention group
Group type: EXPERIMENTAL
Intervention: HD plus Argan oil
Number of subjects: 125
Study 32197408 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 125
Study 32197408 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS-HRQoL
Number of subjects: 125
Study 32343102 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA-guided PDT
Number of subjects: 45
Study 32343102 — intervention group
Group type: COMPARATOR
Intervention: ICGA-guided PDT
Number of subjects: 45
Study 35420044 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Attention, Symbolic Play, Engagement, and Regulation strategies embedded during small group activities
Number of subjects: 0
Study 35420044 — intervention group
Group type: COMPARATOR
Intervention: Standard preschool curriculum
Number of subjects: 0
Study 34242270 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-centered teleconference
Number of subjects: 38
Study 34242270 — intervention group
Group type: COMPARATOR
Intervention: Traditional live-style conference
Number of subjects: 38
Study 32022771 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10010
Study 32022771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 10010
Study 32022771 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin in patients with previous percutaneous coronary intervention
Number of subjects: 10010
Study 32022771 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for both aspirin and clonidine)
Number of subjects: 10010
Study 35564755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-facilitated ACP conversations
Number of subjects: 22
Study 32897367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 679
Study 32897367 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam
Number of subjects: 679
Study 35020171 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive metronome
Number of subjects: 20
Study 35020171 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional metronome
Number of subjects: 20
Study 32306943 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start-Départ Santé (HSDS) intervention group
Number of subjects: 897
Study 32306943 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 897
Study 35889834 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural nitric oxide‐containing soybean lettuce extract
Number of subjects: 40
Study 35889834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33335323 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 (AZD1222) vaccine
Number of subjects: 0
Study 32138630 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Response Technique (RRT) (n = 754)
Number of subjects: 1246
Study 32138630 — intervention group
Group type: COMPARATOR
Intervention: Direct Questioning (DQ) (n = 492)
Number of subjects: 1246
Study 35081564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pulsed-dye laser (PDL) and nonablative fractional laser (NAFL)
Number of subjects: 76
Study 35081564 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 76
Study 34836240 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine tartrate at 50 µM and creatine monohydrate at 0.5 µM combined
Number of subjects: 0
Study 34836240 — intervention group
Group type: COMPARATOR
Intervention: Creatine with LMP formulation at 51 mg/kg
Number of subjects: 0
Study 34836240 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP formulated L-carnitine at 500 mg with LMP formulated creatine at 100, 200, or 500 mg
Number of subjects: 0
Study 33291975 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam intravenous (30 mg once daily)
Number of subjects: 0
Study 33291975 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam intravenous
Number of subjects: 0
Study 33371107 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangji Jianli Capsule (QJC)
Number of subjects: 5
Study 33371107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 33141228 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved vertebroplasty needle (group C)
Number of subjects: 96
Study 33141228 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight vertebroplasty needle (group U)
Number of subjects: 96
Study 33141228 — intervention group
Group type: COMPARATOR
Intervention: Straight vertebroplasty needle (group B)
Number of subjects: 96
Study 33141228 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 96
Study 32024411 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV exercise
Number of subjects: 42
Study 32024411 — intervention group
Group type: COMPARATOR
Intervention: Control (Sham WBV)
Number of subjects: 42
Study 35020038 — intervention group
Group type: EXPERIMENTAL
Intervention: Yigu®
Number of subjects: 458
Study 35020038 — intervention group
Group type: COMPARATOR
Intervention: Aclasta®
Number of subjects: 458
Study 35020038 — intervention group
Group type: EXPERIMENTAL
Intervention: Yigu® and Aclasta®
Number of subjects: 458
Study 33691519 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent ratings of child functioning before treatment
Number of subjects: 100
Study 33691519 — intervention group
Group type: COMPARATOR
Intervention: Clinician ratings of child functioning
Number of subjects: 100
Study 32332545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐aided design and manufacturing cutting and drilling guides with prebent titanium plates
Number of subjects: 46
Study 32332545 — intervention group
Group type: COMPARATOR
Intervention: Computer‐aided design and manufacturing splints
Number of subjects: 46
Study 36303331 — intervention group
Group type: COMPARATOR
Intervention: Adropin levels in Alzheimer's disease (AD) group
Number of subjects: 128
Study 36303331 — intervention group
Group type: COMPARATOR
Intervention: MOTS‐c levels in acute ischemic stroke (AIS) and Alzheimer's disease (AD) groups
Number of subjects: 128
Study 36303331 — intervention group
Group type: COMPARATOR
Intervention: MOTS‐c levels in multiple sclerosis (MS) group
Number of subjects: 128
Study 33069883 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-domain OCT (TD OCT)
Number of subjects: 516
Study 33069883 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized spectral-domain OCT (SD OCT)
Number of subjects: 516
Study 33069883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression modeling for TD OCT
Number of subjects: 516
Study 33069883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression modeling for synthesized SD OCT
Number of subjects: 516
Study 33069883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 32279367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 38
Study 32279367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 35088109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (arms on a pillow)
Number of subjects: 400
Study 35088109 — intervention group
Group type: COMPARATOR
Intervention: Group A (arms repositioned)
Number of subjects: 400
Study 34020837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive pressure treatment for OSA
Number of subjects: 0
Study 34020837 — intervention group
Group type: COMPARATOR
Intervention: Best treatment of each disease separately and recognition and treatment of comorbidities
Number of subjects: 0
Study 34020837 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity surgery when indicated
Number of subjects: 0
Study 32057716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) - 30% of energy needs on fast days
Number of subjects: 260
Study 32057716 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) - 70% of energy needs daily
Number of subjects: 260
Study 32057716 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 260
Study 32057716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 260
Study 32057716 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 260
Study 35130863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (intraoperative warming set to 42 °C)
Number of subjects: 218
Study 35130863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LH (intraoperative warming set to 42 °C for the first hour then set to 38 °C)
Number of subjects: 218
Study 35130863 — intervention group
Group type: COMPARATOR
Intervention: Group L (intraoperative warming set to 38 °C)
Number of subjects: 218
Study 35130863 — intervention group
Group type: COMPARATOR
Intervention: Group L
Number of subjects: 218
Study 35130863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H
Number of subjects: 218
Study 35130863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LH
Number of subjects: 218
Study 34684312 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of L-citrulline
Number of subjects: 12
Study 34684312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35176740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Insight (CI)
Number of subjects: 77
Study 35176740 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping to Conclusions (JTC)
Number of subjects: 77
Study 35176740 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Mind (ToM)
Number of subjects: 77
Study 35176740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive variables
Number of subjects: 77
Study 32408390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg once a day)
Number of subjects: 161
Study 32408390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (50 mg once a day)
Number of subjects: 161
Study 32408390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 161
Study 35655485 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Kyphoplasty (PKP)
Number of subjects: 150
Study 35655485 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Vertebroplasty (PVP)
Number of subjects: 150
Study 35655485 — intervention group
Group type: COMPARATOR
Intervention: Control (Conservative Treatment)
Number of subjects: 150
Study 32935747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sample FIT (FIT 1)
Number of subjects: 289
Study 32935747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sample FIT (FIT 2)
Number of subjects: 289
Study 36250332 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stroking preprocedure
Number of subjects: 112
Study 36250332 — intervention group
Group type: COMPARATOR
Intervention: Parental stroking postprocedure
Number of subjects: 112
Study 33040092 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 49
Study 33040092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 35799169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubus idaeus leaf extract 400 mg
Number of subjects: 198
Study 35799169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubus idaeus leaf extract 200 mg
Number of subjects: 198
Study 35799169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 34002611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 34002611 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 36206494 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with fixed appliances
Number of subjects: 0
Study 36206494 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous dental trauma
Number of subjects: 0
Study 36206494 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontically treated teeth
Number of subjects: 0
Study 34133348 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (EDA) administered intravenously 30 min before surgery
Number of subjects: 160
Study 34133348 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (EDA)
Number of subjects: 160
Study 32916151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (25% of energy requirements)
Number of subjects: 145
Study 32916151 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fructose Corn Syrup (HFCS) (25% of energy requirements)
Number of subjects: 145
Study 32916151 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (25% of energy requirements)
Number of subjects: 145
Study 32916151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose and Glucose interaction (post hoc analysis)
Number of subjects: 145
Study 32916151 — intervention group
Group type: COMPARATOR
Intervention: Aspartame (control)
Number of subjects: 145
Study 37270883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban (25 mcg/kg infused over 5 minutes followed by 0.15 mcg/kg/min for 12-18 hours)
Number of subjects: 100
Study 37270883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban
Number of subjects: 100
Study 37270883 — intervention group
Group type: COMPARATOR
Intervention: Control group (direct PCI during index procedure)
Number of subjects: 100
Study 37270883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 35675613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone pretreatment followed by misoprostol
Number of subjects: 0
Study 35675613 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 0
Study 32556821 — intervention group
Group type: EXPERIMENTAL
Intervention: Franseen-tip needle
Number of subjects: 22
Study 32556821 — intervention group
Group type: COMPARATOR
Intervention: Fork-tip needle
Number of subjects: 22
Study 32556821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 22
Study 34029019 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' knowledge of dental trauma (DT) management
Number of subjects: 1634
Study 34029019 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' training in dental trauma (DT) management
Number of subjects: 1634
Study 34029019 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience with dental trauma (DT) cases
Number of subjects: 1634
Study 34029019 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about tooth avulsion management
Number of subjects: 1634
Study 33170818 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP for women meeting CDC indicators regarding partner characteristics
Number of subjects: 0
Study 33170818 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP for women with a recently incarcerated male partner
Number of subjects: 0
Study 33170818 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP for women with a recently released male partner
Number of subjects: 0
Study 33170818 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples-based PrEP at time of release
Number of subjects: 0
Study 33170818 — intervention group
Group type: COMPARATOR
Intervention: CDC-guideline scenarios
Number of subjects: 0
Study 32314038 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-chemotherapy
Number of subjects: 1202
Study 32314038 — intervention group
Group type: COMPARATOR
Intervention: Rituximab-chemotherapy
Number of subjects: 1202
Study 33484095 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost articulation therapy (BArT)
Number of subjects: 17
Study 33484095 — intervention group
Group type: COMPARATOR
Intervention: Intensive minimal pair training (Control)
Number of subjects: 17
Study 33039958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunotherapy (anti-PD-1 antibody) and antiangiogenic therapy
Number of subjects: 57
Study 37851328 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted maintenance fluid strategy (40%)
Number of subjects: 100
Study 37851328 — intervention group
Group type: COMPARATOR
Intervention: Usual/liberal maintenance fluid strategy (70-80%)
Number of subjects: 100
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E levels in females
Number of subjects: 356
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Interval for Vitamin A
Number of subjects: 356
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Interval for Vitamin E (Total)
Number of subjects: 356
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Interval for Vitamin E (Females)
Number of subjects: 356
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference Interval for Vitamin E (Males)
Number of subjects: 356
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A levels
Number of subjects: 356
Study 33559895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E levels
Number of subjects: 356
Study 32125302 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankel‐2 activator
Number of subjects: 51
Study 32125302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 33390481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd, ENHERTU®)
Number of subjects: 0
Study 32404342 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (4 mg/kg, maximum 300 mg subcutaneous every 4 weeks)
Number of subjects: 36
Study 32404342 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 36
Study 32404342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 36395695 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/day oral conjugated equine estrogens (o-CEE)
Number of subjects: 362
Study 36395695 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg/day transdermal 17β (tE2)
Number of subjects: 362
Study 36395695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 33419674 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine therapy (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids)
Number of subjects: 22065
Study 33419674 — intervention group
Group type: COMPARATOR
Intervention: Reference manual only
Number of subjects: 22065
Study 36475244 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 80
Study 36475244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 80
Study 36475244 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 80
Study 36475244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33279531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) sessions
Number of subjects: 291
Study 33279531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DSME)
Number of subjects: 291
Study 34168271 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal breast milk (MBM)
Number of subjects: 0
Study 34168271 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked donor breast milk (BBM)
Number of subjects: 0
Study 34168271 — intervention group
Group type: EXPERIMENTAL
Intervention: High nutrient intervention diet (preterm formula - PTF)
Number of subjects: 0
Study 34168271 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (term formula - TF)
Number of subjects: 0
Study 34168271 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal infection/NEC
Number of subjects: 0
Study 34402024 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol (500 mg orally once daily for 52 weeks)
Number of subjects: 30
Study 34402024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33407753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation training (four different timelines for four phases of rehabilitation exercises)
Number of subjects: 200
Study 32747036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estradiol (0.5 mg) / dydrogesterone (2.5 mg)
Number of subjects: 0
Study 35377882 — intervention group
Group type: EXPERIMENTAL
Intervention: E-SEE Steps (Incredible Years® Baby Book, targeted Infant/Toddler program if eligible)
Number of subjects: 341
Study 35377882 — intervention group
Group type: EXPERIMENTAL
Intervention: E-SEE Steps
Number of subjects: 341
Study 35377882 — intervention group
Group type: COMPARATOR
Intervention: Control (usual services)
Number of subjects: 341
Study 32662054 — intervention group
Group type: EXPERIMENTAL
Intervention: MindChip™ combined with CBI (Mind Reading©)
Number of subjects: 25
Study 32662054 — intervention group
Group type: COMPARATOR
Intervention: CBI only
Number of subjects: 25
Study 32877969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral leg extensions
Number of subjects: 11
Study 32877969 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral leg extensions
Number of subjects: 11
Study 33645384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit devices
Number of subjects: 11
Study 33645384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fysiogaming
Number of subjects: 11
Study 33645384 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect
Number of subjects: 11
Study 32991656 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-placement (IP) group
Number of subjects: 20